cubes

Selected Publications with PGI Scientists as Authors

Irshad S, Bansal M, Guarnieri P, Davis H, Zen A.L, Baran B, Pinna C.M, Rahman H, Biswas S, Bardella C, Jeffery R, Wang L.M, East J.E, Lewis A, Tomlinson I, Leedham S.J .
BMP and Notch interaction in CRC subtypes 2017doi 10.1002/path.4891.

Alexandrov V, Brunner D, Menalled LB, Kudwa A, Watson-Johnson J, Mazzella M, Russel I, Ruiz MC, Torello J, Sabath E, Sanchez A, Gomez M, Filipov I, Cox K, Kwan M, Ghavami A, Ramboz S, Lager B2, Wheeler VC, Aaronson J, Rosinski J, Gusella JF, MacDonald ME, Howland D, Kwak S.
Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice. 2016 doi:10.1038/nbt.3587

Shao L, Campbell U, Fang K, Powell AN, Campbell JE, Jones PG, Hanania T, Alexandrov V, Morganstern I, Sabath E, Zhong MH, Large HT, Spear KL
In Vivo Phenotypic Drug Discovery: Applying a Behavioral Assay to the Discovery and Optimization of Novel Antipsychotic Agents. Med. Chem. Commun,. 2016 1093-1101

Brunner D., Kabitzke P., He D., Cox K., Thiede L., Hanania T., He D., Sabath E., Alexandrov V., Saxe M., Peles E., Mills A., Spooren W., Ghosh A., Feliciano P., Benedetti M., Clayton AL., Biemans B.
Comprehensive Analysis of the 16p11.2 Deletion and Null Cntnap2 Mouse Models of Autism Spectrum Disorder. PLoS One 2015 10(8); e0134572

Alexandrov V, Brunner D, Hanania T, Leahy E
High-throughput analysis of behavior for drug discovery, European Journal of Pharmacology 750 (2015) 82-89 2015

Henry MA, Fairchild DD, Patil MJ, Hanania, T, Hain HS, Davis SF, Malekiani SA, Hu A., Sucholeiki R, Nix D, Sucholeiki
Effect of a novel, orally active matrix metalloproteinease-2 and-9 inhibitor in spinal and trigeminal rat models of neuropathic pain, Journal of Oral & Facial Pain and Headache 2014

Menalled L & Brunner D.
Animal Models of Huntington’s Disease for Translation to the Clinic: Best Practices. Movement Disorders 29(11): 1375-90 2014

Menalled LB, Kudwa A, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, Mazzella M, He D, Osborne GF, Al-Nackkash R, Bates GP, Tuunanen P, Lehtimaki K, Brunner D, Ghavami A, Ramboz S, Park L, Macdonald D, Munoz-Sanjuan I and Howland D
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington’s disease.PLOS ONE 2014

Balci F, Oakeshott S, Shamy J.S., El-Khodor B.F., Filippov I, Mushlin R, Port R, Connor D, Paintdakhi A, Menalled L, Ramboz S, Howland D, Kwa S, Brunner D
High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington’s Disease. July 2013

Moreno H, Lewandowski N, Bordelon Y, Brickman A, Angulo S, Khan U, Muraskin J, Griffith E, Wasserman P, Menalled L, Vonsattel J.P, Marder K, Small S.A
Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease. Neurobiology of Disease. 2013

Menalled L, Kudwa A, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio B, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, C. Park L, Ramboz S and Howland D
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175 . 2012

Zhang HK, Eaton JB, Yu LF, Nys M, Mazzolari A, van Elk R, Smit AB, Alexandrov V, Hanania T, Sabath E, Fedolak A, Brunner D, Lukas RJ, Vistoli G, Ulens C, Kozikowski AP.
Insights into the Structural Determinants Required for High Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors; An Integrated Approach to Behaviorally Active Nicotinic Ligands. J.Med. Chem., 2012 55(18), pp 8028-8037

S. Stefanie, H Bettina, Nilges M, Schroeder S, Hoelich A, Keletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M, Metzger F.
Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity . 2012

El-Khodor BF, Cirillo K, Beltran JA, Mushlin R, Winberg ML, Charney R, Chomicova O, Marino T, Ramboz S.
Prediction of Death in the SMNΔ Mouse Model of Spinal Muscular Atrophy: Insight into Disease Stage and Progression. Journal of Neuroscience Methods. 2012

Chen PC, Gaisina IN, El-Khodor BF, Ramboz S, Makhortova NR, Rubin LL, Kozikowski AP.
Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Ä7 SMA KO Mouse Model of Spinal Muscular Atrophy. ACS Chem Neurosci. 2012 Jan 18;3(1):5-11.

Menalled, L., El-Khodor, B. F., Hornberger, M., Park, L., Howland, D., and Brunner, D.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice, in PLoS Currents Huntington Disease.. 2012.

Yu, L. F., Tuckmantel, W., Eaton, J. B., Caldarone, B., Fedolak, A., Hanania, T., Brunner, D., Lukas, R. J., and Kozikowski, A. P.
Identification of Novel alpha4 beta2-Nicotinic Acetylcholine Receptor (nAChR) Agonists Based on an Isoxazole Ether Scaffold that Demonstrate Antidepressant-like Activity, Journal of medicinal chemistry. 2012 55, 812-823

Brunner, D., Alexandrov, V., Caldarone, B., Hanania, T., Lowe, D., Schneider, J., and Chandrasekhar, J.
Behavior-Based Screening as an Approach to Polypharmacological Ligands, in Polypharmacology in Drug Discovery (Peters, J.-U., Ed.), pp 301-309, John Wiley & Sons, Inc., Hoboken, New Jersey.. 2012

Efrain Cepeda-Prado, Susanna Popp, Usman Khan, Dimitre Stefanov, Jorge Rodrguez, Liliana Menalled, Diana Dow-Edwards, Scott Small, and Herman Moreno
R6/2 Huntington's disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures. 2012 JN-RM-0388-12R1

Juliette Gafni, Theodora Papanikolaou, Francesco DeGiacomo, Jennifer Holcomb, Sylvia Chen, Menalled L.; Kudwa A.; Jon Fitzpatrick, Miller S.; Ramboz S.; Pasi Tuunanen, Kimmo Lehtimaki, Xiangdong William Yang, Seung Kwak, Larry Park, David Howland, Hyunsun Park, and Lisa Ellerby
Caspase-6 activity in a BAC HD mouse modulates steady state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. 2012 JN-RM-6379-11R1

Brunner, D.; Alexandrov, V.; Chandrasekhar, J.; Hanania, T.; Caldarone, B.; Lowe, D.; Schneider J.
Behavior-based screening as an approach to polypharmacological ligands. In Polypharmacology in Drug Discovery, Peters, J.-U., Ed. John Wiley & Sons, Inc.: Hoboken, New Jersey, 2011 DOI 1D.10.1002/9781118098141.ch4.

Roberds, S. L., Filippov, I., Alexandrov, V., Hanania, T., and Brunner, D.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms, Front Neurosci 2011 5, 103

Oakeshott, S., Port, R. G., Cummins-Sutphen, J., Watson-Johnson, J., Ramboz, S., Park, L., Howland, D., and Brunner, D.
HD mouse models reveal clear deficits in learning to perform a simple instrumental response, PLoS Currents: Huntington Disease.2011 Nov 14.

Liu, J., Yu, L. F., Eaton, J. B., Caldarone, B., Cavino, K., Ruiz, C., Terry, M., Fedolak, A., Wang, D., Ghavami, A., Lowe, D. A., Brunner, D., Lukas, R. J., Kozikowski, A. P.
Discovery of Isoxazole Analogs of Sazetidine-A as Selective alpha4 beta2-Nicotinic Acetylcholine Receptor (nAChR) Partial Agonists for the Treatment of Depression, Journal of medicinal chemistry 2011 54, 7280-7288

Brunner, D., Balci, F., and Ludvig, E. A.
Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration, Behav Processes 2011 89, 187-195

Oakeshott S, Balci F, Filippov I, Murphy C, Port R, Connor D, Paintdakhi A, Lesauter J, Menalled L, Ramboz S, Kwak S, Howland D, Silver R, Brunner D.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease. 2011 Apr 5;3:RRN1225

Liliana M.; El-Khodor B F.; Hornberger M.; Park, Larry; Howland, David; Brunner D.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice [Internet]. Version 28. PLoS Currents: Huntington Disease. 2011 Nov 29 [revised 2012 Feb 15].

Paterson N.E., Wetzler C., Hackett A., Hanania T.
Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat. Int J Neuropsychopharmacol 2011

Steven L Roberts, Filippov I.; Alexandrov V.; Hanania T.; Brunner D.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms. Frontiers in Neuropharmacology. 2011

Paterson, N. E.; Ricciardi, J.; Wetzler, C.; Hanania, T.
Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone. Neurosci Res 2011, 69, 41-50.

Kehr, J.; Ichinose, F.; Yoshitake, S.; Goiny, M.; Sievertsson, T.; Nyberg, F.; Yoshitake, T.
Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 2011.

Oakeshott, S.; Balci, F.; Filippov, I.; Murphy, C.; Port, R.; Connor, D.; Paintdakhi, A.; Lesauter, J.; Menalled, L.; Ramboz, S.; Kwak, S.; Howland, D.; Silver, R.; Brunner, D.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease. PLoS Curr 2011, 3, RRN1225.

Read, R.; Savelieva, K.; Baker, K.; Hansen, G.; Vogel, P.
Histopathological and neurological features of Atg4b knockout mice. Vet Pathol. 2011, 48, 486-94.

Caldarone, B. J.; Wang, D.; Paterson, N. E.; Manzano, M.; Fedolak, A.; Cavino, K.; Kwan, M.; Hanania, T.; Chellappan, S. K.; Kozikowski, A. P.; Olivier, B.; Picciotto, M. R.; Ghavami, A.
Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380. Psychopharmacology (Berl) 2011.

Paterson, N. E.; Balci, F.; Campbell, U.; Olivier, B. E.; Hanania, T.
The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition. J Psychopharmacol 2010.

Paterson, N. E.; Iwunze, M.; Davis, S. F.; Malekiani, S. A.; Hanania, T.
Comparison of the predictive validity of the mirror chamber and elevated plus maze tests in mice. J Neurosci Methods 2010, 188, 62-70.

Baker, K.; Wray, S.; Ritter, R.; Mason, S.; Lanthorn, T.; Savelieva, K.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain and Behavior 2010, 9, 562-574.

Caldarone, B. J.; Paterson, N. E.; Zhou, J.; Brunner, D.; Kozikowski, A. P.; Westphal, K. G.; Korte-Bouws, G. A.; Prins, J.; Korte, S. M.; Olivier, B.; Ghavami, A.
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. J Pharmacol Exp Ther 2010, 335, 762-70.

Paterson, N. E.; Fedolak, A.; Olivier, B.; Hanania, T.; Ghavami, A.; Caldarone, B.
Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 2010, 95, 449-56.

Paterson, N. E.; Min, W.; Hackett, A.; Lowe, D.; Hanania, T.; Caldarone, B.; Ghavami, A.
The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34, 1455-64.

Menalled, L. B.; Patry, M.; Ragland, N.; Lowden, P. A.; Goodman, J.; Minnich, J.; Zahasky, B.; Park, L.; Leeds, J.; Howland, D.; Signer, E.; Tobin, A. J.; Brunner, D.
Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010, 5, e9793.

Baker, K.; Wray, S.; Ritter, R.; Mason, S.; Lanthorn, T.; Savelieva, K.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain and Behavior 2010, 9, 562-574.

Marcellino, D.; Suárez-Boomgaard, D.; Sánchez-Reina, M.D.; Aguirre, J.A.; Yoshitake, T.; Yoshitake, S.; Hagman, B.; Kehr, J.; Agnati, L.F.; Fuxe, K.; Rivera, A.
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm 2010, 117, 681-687.

Galter, D.; Pernold, K.; Yoshitake, T.; Lindqvist, E.; Kehr, J.; Olson, L.
MitoPark mice mirror the slow progression of key Parkinson disease symptoms and the L-DOPA response. Genes, Brain and Behavior 2010, 9, 173-181.

Foreman, M. M.; Hanania, T.; Eller, M.
Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test. Eur J Pharmacol 2009, 602, 316-20.

Nemirovsky, S. I.; Avale, M. E.; Brunner, D.; Rubinstein, M.
Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors. Synapse 2009, 63, 991-7.

Balci, F.; Gallistel, C. R.; Allen, B. D.; Frank, K. M.; Gibson, J. M.; Brunner, D.
Acquisition of peak responding: what is learned Behav Processes 2009, 80, 67-75.

Mason, S. S.; Baker, K. B.; Davis, K. W.; Pogorelov, V. M.; Malbari, M. M.; Ritter, R.; Wray, S. P.; Gerhardt, B.; Lanthorn, T.H.; Savelieva, K.V.
Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. Eur J Pharmacol. 2009, 602, 306-15

Paterson, N. E.
Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol 2009, 603, 1-11.

Paterson, N. E.
The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine. Behav Pharmacol 2009, 20, 211-25.

Paterson, N. E.; Malekiani, S. A.; Foreman, M. M.; Olivier, B.; Hanania, T.
Pharmacological characterization of harmaline-induced tremor activity in mice. Eur J Pharmacol 2009, 616, 73-80.

Menalled, L.; El-Khodor, B. F.; Patry, M.; Suarez-Farinas, M.; Orenstein, S. J.; Zahasky, B.; Leahy, C.; Wheeler, V.; Yang, X. W.; MacDonald, M.; Morton, A. J.; Bates, G.; Leeds, J.; Park, L.; Howland, D.; Signer, E.; Tobin, A.; Brunner, D.
Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 2009, 35, 319-36.

Ye, G-L.; Baker, K.B.; Mason, S.M.; Zhang, W.; Kirkpatrick, L.; Lanthorn, T.H.; Savelieva, K.V.
GABAa receptor α1 subunit (Gabra1) knockout mice: review and new results. In Mutant and Transgenic Tools in Modeling Brain Disorders, Kalueff, AV; Bergner, CL, Ed. Humana Press: 2009, 65-90.

Rajan, I.; Savelieva, K.V.; Ye, G-L.; Wang, C-Y.; Malbari, M. M.; Friddle, C.; Lanthorn, T.H.; Zhang, W.
Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development. PLoS One 2009, 4(8), e6612.

Vinkers, C. H.; van Bogaert, M. J.; Klanker, M.; Korte, S. M.; Oosting, R.; Hanania, T.; Hopkins, S. C.; Olivier, B.; Groenink, L.
Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur J Pharmacol 2008, 585, 407-25.

Day, M.; Balci, F.; Wan, H. I.; Fox, G. B.; Rutkowski, J. L.; Feuerstein, G.
Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Curr Opin Investig Drugs 2008, 9, 696-706.

Savelieva, K. V.; Rajan, I.; Baker, K. B.; Vogel, P.; Jarman, W.; Allen, M.; Lanthorn, T. H.
Learning and memory impairment in Eph receptor A6 knockout mice. Neuroscience letters 2008, 438, 205-209.

Balci, F.; Papachristos, E. B.; Gallistel, C. R.; Brunner, D.; Gibson, J.; Shumyatsky, G. P.
Interval timing in genetically modified mice: a simple paradigm. Genes Brain Behav 2008, 7, 373-84.

Balci, F.; Ludvig, E. A.; Gibson, J. M.; Allen, B. D.; Frank, K. M.; Kapustinski, B. J.; Fedolak, T. E.; Brunner, D.
Pharmacological manipulations of interval timing using the peak procedure in male C3H mice. Psychopharmacology (Berl) 2008, 201, 67-80.

Breuer, M. E.; Chan, J. S.; Oosting, R. S.; Groenink, L.; Korte, S. M.; Campbell, U.; Schreiber, R.; Hanania, T.; Snoeren, E. M.; Waldinger, M.; Olivier, B.
The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 2008, 18, 908-16.

Foreman, M. M.; Hanania, T.; Stratton, S. C.; Wilcox, K. S.; White, H. S.; Stables, J. P.; Eller, M.
In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol Biochem Behav 2008, 89, 523-34.

Houghten, R. A.; Pinilla, C.; Giulianotti, M. A.; Appel, J. R.; Dooley, C. T.; Nefzi, A.; Ostresh, J. M.; Yu, Y.; Maggiora, G. M.; Medina-Franco, J. L.; Brunner, D.; Schneider, J.
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. J Comb Chem 2008, 10, 3-19.

Balci, F.; Moore, H.; Brunner, D.
Timing Deficits in Neuropathology In Cognitive Aging: Integrating Models. Humana Press: Wagner, L.A., 2008.

El-Khodor, B. F.; Edgar, N.; Chen, A.; Winberg, M. L.; Joyce, C.; Brunner, D.; Suarez-Farinas, M.; Heyes, M. P.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol 2008, 212, 29-43.

Menalled, L.; Gomeniouk, A.; Brunner, D.; Leavitt, B. R.
Huntington Disease. In Animal and Translational Models of Behavioral Disorders Borsini, R. M. a. F., Ed. Elsevier: 2008.

Balci, F.; Papachristos, E. B.; Gallistel, C. R.; Brunner, D.; Gibson, J.; Shumyatsky, G. P.
Interval timing in genetically modified mice: a simple paradigm. Genes Brain Behav 2008, 7, 373-84.

El-Khodor, B. F.; Edgar, N.; Chen, A.; Winberg, M. L.; Joyce, C.; Brunner, D.; Suarez-Farinas, M.; Heyes, M. P.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol 2008, 212, 29-43.

Pogorelov, V.M.; Baker, K.B.; Malbari, M.M.; Lanthorn, T.H.; Savelieva, K.V.
Standardized Behavioral Test Battery to Identify and Validate Targets for Neuropsychiatric Diseases and Pain. In Experimental models in neurobehavioral research, Kalueff AV, LaPorte JL, Ed. Nova Science Publishers: 2008, 17-46.

Savelieva, K.V.; Zhao, S.; Pogorelov, V.M.; Rajan, I.; Yang, Q.; Cullinan, E.; Lanthorn, T.H.
Genetic disruption of both tryptophan hydroxylase genes strongly reduces serotonin in the brain and affects behavior in models sensitive to antidepressants. PLoS One 2008, 3(10), e3301.

Zhang, W.; Rajan, I.; Savelieva, K.V.; Wang, C-Y.; Vogel, P.; Kelly, M.; Xu, N.; Hasson, B.; Jarman, W.; Lanthorn, T.H.
Netrin-G2 and netrin-G2 ligand are both required for normal auditory responsiveness. Genes Brain Behav. 2008,7(4), 385-92.

Balci, F.; Papachristos, E. B.; Gallistel, C. R.; Brunner, D.; Gibson, J.; Shumyatsky, G. P.
Interval timing in genetically modified mice: a simple paradigm. Genes Brain Behav 2008, 7, 373-84.

Savelieva, K. V.; Rajan, I.; Baker, K. B.; Vogel, P.; Jarman, W.; Allen, M.; Lanthorn, T. H.
Learning and memory impairment in Eph receptor A6 knockout mice. Neuroscience letters 2008, 438, 205-209.

Zhang, W.; Rajan, I.; Savelieva, K.V.; Wang, C-Y.; Vogel, P.; Kelly, M.; Xu, N.; Hasson, B.; Jarman, W.; Lanthorn, T.H.
Netrin-G2 and netrin-G2 ligand are both required for normal auditory responsiveness. Genes Brain Behav. 2008,7(4), 385-92.

Pogorelov, V.M.; Lanthorn, T.H.; Savelieva KV.
Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice. J Neurosci Methods 2007 162(1-2), 222-8.

Kehr, J
New methodological aspects of microdialysis. Elsevier: The Netherlands, 2007.

Kehr, J.; Hu, X. J.; Goiny, M.; Scheller, D. K.
Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007, 114, 1027-31.

Roy, K.; Murtie, J. C.; El-Khodor, B. F.; Edgar, N.; Sardi, S. P.; Hooks, B. M.; Benoit-Marand, M.; Chen, C.; Moore, H.; O'Donnell, P.; Brunner, D.; Corfas, G.
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci U S A 2007, 104, 8131-6.

Shankaran, M.; Marino, M. E.; Busch, R.; Keim, C.; King, C.; Lee, J.; Killion, S.; Awada, M.; Hellerstein, M. K.
Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery. J Neurosci Res 2007, 85, 2374-84.

Busch, R.; Neese, R. A.; Awada, M.; Hayes, G. M.; Hellerstein, M. K.
Measurement of cell proliferation by heavy water labeling. Nat Protoc 2007, 2, 3045-57.

Kozikowski, A. P.; Gaisina, I. N.; Yuan, H.; Petukhov, P. A.; Blond, S. Y.; Fedolak, A.; Caldarone, B.; McGonigle, P.
Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc 2007, 129, 8328-32.

Herrera-Marschitz, M.; Bustamante, D.; Morales, P.; Goiny, M.
Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins. Neurotox Res 2007, 11(3-4), 169-82.

Kehr, J.; Hu, X.J.; Goiny, M.; Scheller, D.K.
Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007, 114, 1027-1031.

Kehr, J.; Hu, X.J.; Yoshitake, T.; Scheller, D.
Determination of the dopamine agonist rotigotine in microdialysates from the rat brain by microbore column liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 845, 109-113.

Cagniard, B.; Balsam, P. D.; Brunner, D.; Zhuang, X.
Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 2006, 31, 1362-70.

Kehr, J.; Yoshitake, T.
Monitoring brain chemical signals by microdialysis. American Scientific Publishers: USA, 2006; Vol. 6.

Shankaran, M.; King, C.; Lee, J.; Busch, R.; Wolff, M.; Hellerstein, M. K.
Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique. J Pharmacol Exp Ther 2006, 319, 1172-81.

Rothstein, J. D.; Patel, S.; Regan, M. R.; Haenggeli, C.; Huang, Y. H.; Bergles, D. E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D. S.; Toan, S. V.; Bruijn, L. I.; Su, Z. Z.; Gupta, P.; Fisher, P. B.
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433, 73-7.

Menalled, L. B.
Knock-in mouse models of Huntington's disease. NeuroRx 2005, 2, 465-70.

Aguirre, J.A.; Kehr, J.; Yoshitake, T.; Liu, F.L.; Rivera, A.; Fernandez-Espinola, S.; Andbjer, B.; Leo, G.; Medhurst, A.D.; Agnati, L.F.; Fuxe, K.
Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 2005, 1033, 216-20.

Compan, V.; Zhou, M.; Grailhe, R.; Gazzara, R. A.; Martin, R.; Gingrich, J.; Dumuis, A.; Brunner, D.; Bockaert, J.; Hen, R.
Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice. J Neurosci 2004, 24, 412-9.

El-Khodor, B. F.; Dimmler, M. H.; Amara, D. A.; Hofer, M.; Hen, R.; Brunner, D.
Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation. Int J Dev Neurosci 2004, 22, 405-13.

Weikop, P.; Egestad, B.; Kehr, J.
Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. J Neurosci Methods 2004, 140, 59-65.

Yoshitake, T.; Wang, F. H.; Kuteeva, E.; Holmberg, K.; Yamaguchi, M.; Crawley, J. N.; Steiner, R.; Bartfai, T.; Ogren, S. O.; Hokfelt, T.; Kehr, J.
Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test. Proc Natl Acad Sci U S A 2004, 101, 354-9.

Tanganelli, S.; Sandager Nielsen, K.; Ferraro, L.; Antonelli, T.; Kehr, J.; Franco, R.; Ferre, S.; Agnati, L.F.; Fuxe, K.; Scheel-Kruger, J.
Striatal plasticity at the network level. Focus on adenosine A(2A) and D(2) interactions in models of Parkinson's Disease. Parkinsonism Relat Disord 2004, 10, 273-80.

Bustamante, D.; Bustamante, L.; Segura-Aguilar, J.; Goiny, M.; Herrera-Marschitz, M.
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats. Neurotox Res. 2004 5(8):569-77

Olivier, B.; Zethof, T.; Pattij, T.; van Boogaert, M.; van Oorschot, R.; Leahy, C.; Oosting, R.; Bouwknecht, A.; Veening, J.; van der Gugten, J.; Groenink, L.
Stress-induced hyperthermia and anxiety: pharmacological validation. Eur J Pharmacol 2003, 463, 117-32.

Brunner, D.; Nestler, E.; Leahy, E.
In need of high-throughput behavioral systems. Drug Discov Today 2002, 7, S107-12.

Stefansson, H.; Sigurdsson, E.; Steinthorsdottir, V.; Bjornsdottir, S.; Sigmundsson, T.; Ghosh, S.; Brynjolfsson, J.; Gunnarsdottir, S.; Ivarsson, O.; Chou, T. T.; Hjaltason, O.; Birgisdottir, B.; Jonsson, H.; Gudnadottir, V. G.; Gudmundsdottir, E.; Bjornsson, A.; Ingvarsson, B.; Ingason, A.; Sigfusson, S.; Hardardottir, H.; Harvey, R. P.; Lai, D.; Zhou, M.; Brunner, D.; Mutel, V.; Gonzalo, A.; Lemke, G.; Sainz, J.; Johannesson, G.; Andresson, T.; Gudbjartsson, D.; Manolescu, A.; Frigge, M. L.; Gurney, M. E.; Kong, A.; Gulcher, J. R.; Petursson, H.; Stefansson, K.
Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71, 877-92.

Brunner, D.; Kacelnik, A.
Timing and Foraging: Gibbon's Scalar Expectancy Theory and Optimal Patch Exploitation. Animal Learning and Behavior 2001, 1, 177-190.

Abner, R.; Edwards, T.; Brunner, D.
Pharmacology of Temporal Cognition in Two Mouse Strains. Special issue of the International Journal of Comparative Psychology 2001, 14, 189-210.

Olivier, B.; Leahy, C.; Mullen, T.; Paylor, R.; Groppi, V. E.; Sarnyai, Z.; Brunner, D.
The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics Psychopharmacology (Berl) 2001, 156, 284-90.

Grailhe, R.; Waeber, C.; Dulawa, S. C.; Hornung, J. P.; Zhuang, X.; Brunner, D.; Geyer, M. A.; Hen, R.
Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron 1999, 22, 581-91.

Kehr, J.
Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques. In Modern techniques in neuroscience research, Johansson, U. W. a. H., Ed. Springer-Verlag GmbH: Heidelberg, Germany, 1999; pp 1149-1198.

Ramboz, S.; Oosting, R.; Amara, D. A.; Kung, H. F.; Blier, P.; Mendelsohn, M.; Mann, J. J.; Brunner, D.; Hen, R.
Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A 1998, 95, 14476-81.

 

  • PsychoGenics
  • 765 Old Saw Mill River Road, Tarrytown, NY 10591
  • tel: (914) 406-8019
  • fax: (914) 593-0645